

About HoHo Bioteh and Founder.
結論:我做食品 + 醫療研究
食品 輔助現有的用藥 帶動現金收入
我們有專利 醫療研究為了授權藥廠醫療使用
最近
1. 2025/2 美國FDA 官網已認定氫治療ALS漸凍症的潛力
2. 2025/4 有氫醫療專利團隊被收購
3. 募資USD$ 5M
HOHO's LinkedIn:
www.linkedin.com/company/hoho-biotech
Benson's LinkedIn:
https://www.linkedin.com/in/kuang-yih-wang-ab14b621/
I’m Benson Wang, founder of HOHO Biotech.
With over 20 years in biomedical innovation and a background in neurogenetics, I focus on developing Molecular Hydrogen Capsules as a clinically proven Adjuvant to enhance Immune balance and Reduce Drug Side Effects. My mission is to make hydrogen-based precision therapies accessible to patients worldwide.
HoHo Biotech was founded in 2017.
The company focuses on Autoimmune Disease, Hydrogen-Based Molecular Medicine, and gut microenvironment research.
In 2018, it developed a "Hydrogen Capsule", a proprietary natural coral calcium material.
In 2020, it received TFDA approval, becoming a "Prescription use in Regional Hospital", based on clinical trial data.
In 2022, it became a "Prescription Use in Medical Center".
In 2024, Launched H2 Capsule in "Pharmacy Chains", more than 200 shops.
In 2024, HoHo introduced an AI molecular simulation system and built the Molecular Intelligence Engine, combining functional material science with computational modeling.
In 2025, published more than 18+ Medical Papers as evidence of the "Hydrogen Capsule" as a perfect "Adjuvant" in the Autoimmune area.
Launched HydroChat, an AI assistant for personalized applications. This development led to the company’s core strategy, Gut Engineering, which uses molecular signals to regulate the intestinal environment.